申请人:Warner-Lambert Company
公开号:US05236926A1
公开(公告)日:1993-08-17
The present invention is novel 9-substituted-8-hydroxy or -8-halo-9 deazaguanines and pharmaceutical compositions and methods of use therefor. The derivatives are inhibitors of purine nucleoside phosphorylase selectively cytotoxic to T-cells but not to B-cells in the presence of 2'-deoxyguanosine and, therefore, are for use in the treatment of autoimmune diseases, gout, psoriasis or rejection of transplantation.
本发明涉及一种新型的9-取代-8-羟基或8-卤代-9脱氧鸟嘌呤及其药物组合物和使用方法。这些衍生物是嘌呤核苷酸磷酸化酶抑制剂,对T细胞有选择性细胞毒作用,但在存在2'-去氧鸟苷时对B细胞没有毒性,因此可用于治疗自身免疫性疾病、痛风、牛皮癣或移植排斥反应。